Jill Bracken, DO
Child & Adolescent Psychiatry · Garland, TXNPI 1710053319
Payments from drug & device makers
Across 91 payments — averaging $10.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$360
- Sunovion Pharmaceuticals Inc.$259
- AbbVie$218
- Supernus Pharmaceuticals, Inc.$83
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$49
- Ironshore Pharmaceuticals Inc.$15
What the payments were for
- Food & beverage$93595%
- Education$495%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 21 | $360 |
| Sunovion Pharmaceuticals Inc. | 46 | $259 |
| AbbVie | 17 | $218 |
| Supernus Pharmaceuticals, Inc. | 5 | $83 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $49 |
| Ironshore Pharmaceuticals Inc. | 1 | $15 |
How this compares
$984 in reported general payments places this provider in the 70th percentile of 301 child & adolescent psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lisdexamfetamine Dimesylate | 11 | $3,397 |
| Clozapine | 29 | $2,025 |
| Ziprasidone Hcl | 42 | $1,634 |
| Clonidine Hcl ErClonidine Hcl | 11 | $1,435 |
| Trazodone Hcl | 21 | $1,137 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 30 | $1,002 |
| Guanfacine Hcl | 18 | $883 |
| Duloxetine Hcl | 18 | $841 |
| Lamotrigine | 29 | $808 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 19 | $630 |
| Eszopiclone | 25 | $553 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 12 | $502 |
| Bupropion XlBupropion Hcl | 16 | $487 |
| Alprazolam | 44 | $450 |
| Clonazepam | 47 | $445 |
Paid to pharmacies, not to this prescriber.
Other child & adolescent psychiatry in Garland
- Alain KaticBellaire$1.6M
- Steven PliszkaSan Antonio$194K
- Humera ChowdharyDenton$120K
- Farida AliFort Worth$75K
- Graham EmslieDallas$73K
- Rosa GonzalezBeaumont$55K
- Mary Garcia HolguinSan Antonio$24K
- Jeremy LankfordHouston$20K
- Cristian ZeniHouston$15K
- John SteffekSpring$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.